ES2307760T3 - Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. - Google Patents
Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. Download PDFInfo
- Publication number
- ES2307760T3 ES2307760T3 ES02735312T ES02735312T ES2307760T3 ES 2307760 T3 ES2307760 T3 ES 2307760T3 ES 02735312 T ES02735312 T ES 02735312T ES 02735312 T ES02735312 T ES 02735312T ES 2307760 T3 ES2307760 T3 ES 2307760T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- methyl
- lhrh antagonist
- dementia
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 12
- 206010012289 Dementia Diseases 0.000 title claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 6
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 9
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims abstract description 4
- 229960003230 cetrorelix Drugs 0.000 claims abstract description 4
- 108700008462 cetrorelix Proteins 0.000 claims abstract description 4
- 239000000816 peptidomimetic Substances 0.000 claims abstract description 4
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims abstract description 3
- 108010023617 abarelix Proteins 0.000 claims abstract description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims abstract description 3
- 229960002184 abarelix Drugs 0.000 claims abstract description 3
- 108010070670 antarelix Proteins 0.000 claims abstract description 3
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims abstract description 3
- 108010083551 iturelix Proteins 0.000 claims abstract description 3
- 229950011372 teverelix Drugs 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract 2
- -1 3,5-dimethylphenyl Chemical group 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- QGGCIYXVQZHCKK-UHFFFAOYSA-N 3-[[[2-[1-(3,5-difluorophenyl)-3-(2-methoxyphenyl)-1,3-dioxopropan-2-ylidene]-1,3-dihydrobenzimidazol-5-yl]amino]methyl]benzonitrile Chemical compound COC1=CC=CC=C1C(=O)C(C(=O)C=1C=C(F)C=C(F)C=1)=C1NC2=CC(NCC=3C=C(C=CC=3)C#N)=CC=C2N1 QGGCIYXVQZHCKK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 description 10
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 8
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 7
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 7
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 159000000021 acetate salts Chemical group 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| US287434P | 2001-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2307760T3 true ES2307760T3 (es) | 2008-12-01 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02735312T Expired - Lifetime ES2307760T3 (es) | 2001-04-30 | 2002-04-27 | Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (enExample) |
| EP (1) | EP1392348B1 (enExample) |
| JP (1) | JP2004529207A (enExample) |
| KR (1) | KR20040000446A (enExample) |
| CN (1) | CN1317030C (enExample) |
| AT (1) | ATE400287T1 (enExample) |
| AU (1) | AU2002310788B2 (enExample) |
| BG (1) | BG108339A (enExample) |
| BR (1) | BR0209290A (enExample) |
| CA (1) | CA2444876A1 (enExample) |
| CZ (1) | CZ20033167A3 (enExample) |
| DE (1) | DE60227507D1 (enExample) |
| DK (1) | DK1392348T3 (enExample) |
| ES (1) | ES2307760T3 (enExample) |
| HU (1) | HUP0400067A2 (enExample) |
| IL (1) | IL156777A0 (enExample) |
| MX (1) | MXPA03008666A (enExample) |
| NO (1) | NO20034322L (enExample) |
| NZ (1) | NZ544417A (enExample) |
| PL (1) | PL362319A1 (enExample) |
| PT (1) | PT1392348E (enExample) |
| RU (1) | RU2319501C2 (enExample) |
| SI (1) | SI1392348T1 (enExample) |
| SK (1) | SK14512003A3 (enExample) |
| UA (1) | UA80679C2 (enExample) |
| WO (1) | WO2002102401A1 (enExample) |
| ZA (1) | ZA200305326B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| DK1300398T3 (da) | 2000-07-05 | 2006-07-17 | Astellas Pharma Inc | Propan-1,3-dionderivat |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| JP4595938B2 (ja) | 2004-06-04 | 2010-12-08 | アステラス製薬株式会社 | プロパン−１，３−ジオン誘導体又はその塩 |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| ES2445791T3 (es) | 2006-10-21 | 2014-03-05 | Abbvie Deutschland Gmbh & Co Kg | Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3 |
| US20100204143A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| WO2009049742A2 (en) * | 2007-09-11 | 2009-04-23 | Mondobiotech Laboratories Ag | Use of melanotrophin-potentiating factor as a therapeutic agent |
| EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| CA2726247C (en) * | 2008-05-29 | 2018-06-26 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| EP0901489A1 (en) * | 1996-05-20 | 1999-03-17 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| NZ515460A (en) * | 1999-05-14 | 2004-06-25 | Neurocrine Biosciences Inc | Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| DE60022769T2 (de) * | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| AU2001248760A1 (en) | 2000-04-13 | 2001-10-30 | Takeda Chemical Industries Ltd. | Preventives/remedies for alzheimer's disease |
| DK1300398T3 (da) | 2000-07-05 | 2006-07-17 | Astellas Pharma Inc | Propan-1,3-dionderivat |
-
2002
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2444876A1 (en) | 2002-12-27 |
| US7288517B2 (en) | 2007-10-30 |
| PT1392348E (pt) | 2008-09-09 |
| PL362319A1 (en) | 2004-10-18 |
| KR20040000446A (ko) | 2004-01-03 |
| BG108339A (bg) | 2004-11-30 |
| HUP0400067A2 (hu) | 2004-04-28 |
| WO2002102401A1 (en) | 2002-12-27 |
| JP2004529207A (ja) | 2004-09-24 |
| UA80679C2 (en) | 2007-10-25 |
| ZA200305326B (en) | 2003-07-30 |
| SI1392348T1 (sl) | 2008-12-31 |
| DE60227507D1 (de) | 2008-08-21 |
| NZ544417A (en) | 2008-03-28 |
| HK1072000A1 (en) | 2005-08-12 |
| EP1392348A1 (en) | 2004-03-03 |
| MXPA03008666A (es) | 2004-10-15 |
| ATE400287T1 (de) | 2008-07-15 |
| US20020177556A1 (en) | 2002-11-28 |
| AU2002310788B2 (en) | 2007-04-05 |
| RU2319501C2 (ru) | 2008-03-20 |
| BR0209290A (pt) | 2004-07-13 |
| NO20034322D0 (no) | 2003-09-26 |
| CN1575185A (zh) | 2005-02-02 |
| EP1392348B1 (en) | 2008-07-09 |
| SK14512003A3 (sk) | 2004-08-03 |
| CN1317030C (zh) | 2007-05-23 |
| IL156777A0 (en) | 2004-02-08 |
| RU2003134949A (ru) | 2005-02-10 |
| NO20034322L (no) | 2003-09-26 |
| CZ20033167A3 (cs) | 2004-08-18 |
| DK1392348T3 (da) | 2008-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2307760T3 (es) | Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. | |
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| EP1663236B1 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| US20080032935A1 (en) | Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits | |
| DE69927705T2 (de) | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse | |
| ES2247710T3 (es) | Antagonista de gonadotropina. | |
| JP3176051B2 (ja) | 避妊方法とその組成物 | |
| RU2002111000A (ru) | Способ терапевтического лечения внематочной пролиферации эндометриальной ткани, хронической боли в области таза и непроходимости фаллопиевых труб, фармацевтическая композиция и анатагонист LHRH-лекарственное средство для указанного лечения (варианты) | |
| HK1049117A1 (zh) | 用於治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗助的方法 | |
| JPWO2021089678A5 (enExample) | ||
| HU226374B1 (en) | Pharmaceutical combination of a bradykinin antagonist and an antiviral agent | |
| KR102494794B1 (ko) | 여성 성기능장애의 치료를 위한 약학 조성물 및 방법 | |
| CA1326439C (en) | Parenteral growth hormone formulations | |
| JPH04506969A (ja) | 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用 | |
| US20100279944A1 (en) | Suppression and treatment of neuropathic pain | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| HK1090294B (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| HK1107262A (en) | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction | |
| HK1126131A (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |